Adalimumab Market Growth, Trend, Price and Forecast to 2024 Adalimumab Market - Global Industry Analysis, Size

Adalimumab Market - Global Industry Analysis,
Size, Share, Growth, Trends, and Forecast 2016
- 2024
Global Adalimumab Market: Overview
Adalimumab, with a trade name of Humira and Exemptia, is an anti-TNF drug used
for treating rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and
ulcerative colitis. Adalimumab usually binds with tumor necrosis factor-alpha
(TNFα). When a TNFα binds to a TBFα receptors, it results in an inflammatory
response to autoimmune disease. Adalimumab, by binding to a TNFα, lowers the
chances of inflammatory response.
Adalimumab, which was first approved in the U.S., is currently being marketed in
over 60 countries. Its global market is consolidated with a handful of players trying
to outsmart one another on the basis of price. At present, most of the leading
players are focused on the development of adalimumab biosimilars for curing
rheumatoid arthritis and psoriasis. This is palpable from the clinical trials being
carried out to test the safety and efficacy of the adalimumab biosimilars in curing
the medical conditions.
A report by Transparency Market Research studies the global adalimumab market in
details. It presents a qualitative analysis of the different market trends and gauges
its size and potential. It also throws light on the different production plants, their
capacities, global production, and revenues. To do so, extensive primary and
secondary researches have been carried out.
Browse To Report @
http://www.transparencymarketresearch.com/adalimumab-market.html
Global Adalimumab Market: Drivers and Restraints
At the forefront of driving the global adalimumab market is the rising occurrence of
arthritis worldwide. This in turn is mostly on account of the burgeoning elderly
population. In fact, most women suffer from arthritis in old age because of loss of
calcium in the body. A sedentary lifestyle is also responsible for growth in arthritis
and another medical condition called psoriasis. Both of them along with other
factors such as rising prevalence of Crohn’s disease and ulcerative colitis are
leading to the uptake of the product.